Hepatitis viruses belong to different families and have in common a striking hepatotropism and restrictions for propagation in cell culture. The transmissibility of hepatitis is in great part limited to non-human primates. Enterically transmitted hepatitis viruses (hepatitis A virus and hepatitis E virus) can induce hepatitis in a number of Old World and New World monkey species, while the host range of non-human primates susceptible to hepatitis viruses transmitted by the parenteral route (hepatitis B virus, hepatitis C virus and hepatitis delta virus) is restricted to few species of Old World monkeys, especially the chimpanzee. Experimental studies on non-human primates have provided an invaluable source of information regarding the biology and pathogenesis of these viruses, and represent a still indispensable tool for vaccine and drug testing. 
Introduction
Viral hepatitis represents a global public health problem. There are at least five viruses that classically cause hepatitis in man: hepatitis A virus (HAV) and hepatitis E virus (HEV) transmitted by the fecal-oral route and causing only acute, self-limited infections, and hepatitis B virus (HBV), hepatitis C virus (HCV) and hepatitis delta virus (HDV) transmitted by blood and other body fluids with the possibility of persistence and development of liver cirrhosis and primary hepatocellular carcinoma (HCC). The recently identified hepatitis G virus (HGV) has not been definitively associated with any disease (1) . These viruses belong to different families and have in common a striking hepatotropism and substantial restrictions for propagation in conventional cell cultures. HAV may be an exception to this rule in that it is amenable to propagation in several types of primate cell cultures (2) . However, except for some fast-growing HAV isolates (3), its replication is remarkably slow, and nearly always non-cytopathic. For this reason, transmission of hepatitis viruses to non-human primates, the only available animal model, is an invaluable tool for the propagation of these viruses, as well as for studies of their biology and pathogenesis.
Historical aspects
Attempts to transmit human hepatitis to non-human primates were generally unsuc-cessful until the 1960s. Prior to this period, no approach was available to determine the infectivity of the inoculum or the previous immune status of the animals (4). The interest in non-human primates as models for hepatitis was stimulated when natural transmission of hepatitis from primates to man was reported at a U.S. Air Force base (5) . In 1962, Deinhardt et al. (6) described biochemical and histopathologic changes during an episode of mild hepatitis in chimpanzees inoculated with acute-phase serum or feces from patients with a disease that had the epidemiologic characteristics of hepatitis A. In 1967, the same group reported transmission of an agent of hepatitis to marmosets using acute-phase serum from a surgeon (initials GB) with hepatitis (7) . The latter results were contested by the evidence that hepatitis in the marmosets may have resulted from the reactivation of a latent marmoset hepatitis agent (8) . Transmission of HAV was confirmed by inoculation of marmosets and chimpanzees with acutephase sera and feces from HAV-infected human volunteers (9, 10) . Soon after these events, the discovery of Australia antigen (or HBsAg) (11) and the identification of HAV (12) were reported, leading to the development of the first serological assays for hepatitis A and hepatitis B.
Subsequently, it was realized that many epidemics of enterically transmitted hepatitis were not caused by HAV and that most cases of posttransfusion hepatitis were due to an agent other than HBV. These cases were termed enterically and parenterally transmitted non-A, non-B hepatitis (ET-NANBH and PT-NANBH, respectively). Primate models for experimental infections with the agent of PT-NANBH were developed in the late 1970s with the demonstration that specimens from patients infected with non-A, non-B hepatitis readily produced hepatitis in chimpanzees (13) (14) (15) . The causative agent of PT-NANBH was only identified in 1989, when the application of recombinant DNA technology made possible the identification of hepatitis C virus (HCV) specific nucleic acid (16) , and the development of the first specific serologic assay (17) . Critical to the success of this approach was the availability of large volumes (2,500 ml) of high-titer chimpanzee plasma from which sufficient cDNA could be produced. HCV represents the predominant cause of transfusion-associated hepatitis around the world as well as a major cause of liver cirrhosis and HCC (18) .
Transmission of ET-NANBH to non-human primates was first reported in 1983 by Balayan et al. (19) , who successfully inoculated intravenously (iv) a 10%-w/v stool suspension from a human volunteer that was positive by immune electron microscopy for virus-like particles 27-30 nm in diameter. Transmission to monkeys remained the only means of studying ET-NANBH until 1990, when Reyes et al. (20) cloned and sequenced part of the viral genome. The complete sequence of the viral genome is now known and the agent, renamed hepatitis E virus (HEV), is considered to be the major cause of sporadic hepatitis in Asia, Africa and India (21) .
The identification of HDV occurred in the mid-70s with the detection of a previously unrecognized nuclear antigen in hepatocyte nuclei of an Italian patient with chronic hepatitis B (22) . The antigen, called delta antigen (HDAg), was initially believed to be a previously unnoticed hepatitis B-specific antigen. Transmission experiments in chimpanzees were published in 1980 (23) . Chimpanzees were the only animals known at that time to be susceptible to HBV infection, and supposedly permissive to HDAg expression. Those studies confirmed that HDAg was a component of a defective transmissible pathogen that required coinfection with HBV for its replication. Epidemiologic studies showed that hepatitis associated with expression of HDAg was highly endemic in Italy and among several populations from South Ame-rica, including Brazil (24) . By 1983, the HDAg was designated as a distinct hepatitis virus, the hepatitis D or delta virus (HDV) (25) .
After reliable immunoassays and molecular probes became available for the detection of HCV and HEV infections, it was evident that 10-20% of non-A, non-B hepatitis cases were not caused by HCV or HEV. One of the first hepatitis agents to be transmitted to non-human primates originated from the serum of a surgeon (initials GB) obtained on the third day of jaundice (7) . Tamarins inoculated with serum from this patient developed hepatitis, as did tamarins inoculated in serial passage studies. The putative etiologic agent was called the GB agent. In 1995, Simons and co-workers (26) identified two viruses, GB virus A (GBV-A) and GB virus B (GBV-B) in the acute phase serum of a tamarin that developed hepatitis following inoculation with serum from the 11th tamarin passage of the GB agent. Both viruses were shown to be related to viruses of the family Flaviviridae, in particular to HCV. However, the origin of these viruses remains unknown, and neither one has been detected in humans. Recently, Bukh and Apgar (27) analyzed sera from 98 wild-caught New World monkeys representing 10 different species, and found that many of these monkeys seem to be persistently infected with GBV-A. In 1996, a third virus named GB virus C (GBV-C) or hepatitis G virus (HGV), more closely related to GBV-A, was identified in humans by two research groups (28, 29) . GBV-C and HGV share 86% of their nucleotide sequences and 96% of their deduced amino acid sequences, and are believed to be two isolates of the same virus. HGV was detected not only in patients with acute, chronic, and fulminant hepatitis, persons with history of blood transfusion, patients on hemodialysis, and intravenous drug users, but also in health blood donors (30). For this reason, HGV is not definitely associated with any disease (1).
Transmission of hepatitis viruses to non-human primates
Non-human primates have played an essential role in the understanding of the various forms of viral hepatitis. A different range of monkeys are susceptible to hepatitis viruses, as summarized in Table 1 .
Enterically transmitted hepatitis viruses

Hepatitis A virus (HAV)
Experimental studies of HAV infection have been carried out in several non-human primates, including both Old World and New World monkeys, as listed in Table 1 . We HAV-induced disease in non-human primates resembles human disease, but is usually milder, or subclinical, followed by complete recovery. Similar to human hepatitis, relapsing courses of hepatitis A have also been reported in experimentally infected monkeys (35-37). After infection by the intragastric or iv route, HAV or viral antigen is first detected in hepatocytes, then in serum, bile and feces. These events precede liver injury, which appears concomitantly with the seroconversion.
C. jacchus has been the non-human primate of choice in our experimental infection studies with HAV because it is readly available, easy to handle and highly susceptible to HAV (33,34,38). In this model, several pathological aspects of HAV infection can be analyzed, such as the mechanism involved in liver cell injury and the possibility of extrahepatic sites of HAV replication. After intragastric or iv infection, HAV antigen (HAVAg) is detected in feces and liver in the absence of detectable alanine aminotransferase (ALT) elevation or hepatocellular changes (33,34,38). The diagnosis of enhanced hepatic lesions coincides with seroconversion and expression of interleukin 6 and inducible nitric oxide synthase, while HAVAg was not detected in feces and liver, or was present in small amounts (Pinto MA, personal communication). These findings suggest an immune-mediated mechanism of hepatic injury rather than a direct cytopathic effect, a hypothesis supported by other experimental studies (39,40). How the virus reaches the liver and the existence of non-hepatic sites of primary viral replication are matters as yet undefined. It has been assumed that after ingestion HAV reaches the liver where it replicates before being excreted through the bile into the intestine, since its detection in the intestinal mucosa or any other organ except the liver has been inconsistent (40-43). Our own experiments with immunohistochemistry revealed extrahepatic HAVAg in the kidney, spleens, lymph nodes and small intestine (33,38). However, this may represent humoral immune clearance rather than active viral replication, as also suggested by others (43,44).
Spontaneous outbreaks of hepatitis A have been reported in captive non-human primates including owl monkeys, cynomolgus monkeys, rhesus monkeys, stump-tailed and African green monkeys (45). The presence of anti-HAV antibody in the sera of newly captured monkeys of these species shows that infection may also spread in their natural habitat. HAV strains have been recovered from several of these species in captivity, but it is still unknown whether these viruses were acquired from humans (45). Preliminary molecular analysis of some of these strains suggests that they are sufficiently different from known human strains to be considered as separate simian viruses. Infection of monkeys with such strains results in hepatitis and at least partial protection against challenge with human HAV strains. Nevertheless, recent data have shown that the AGM-27 strain isolated from an African green monkey failed to produce hepatitis in chimpanzees (46), but elicited protective anti-HAV responses, suggesting that it may be naturally attenuated for higher primates.
The production of biological specimens represents one of the applications of nonhuman primates in experimental infections with HAV. Feces can be collected at the end of the incubation period, representing the most abundant and accessible source of HAV, and liver biopsies can also be performed during the acute phase of infection. Moreover, development of specific antibodies can be monitored for the production of hyperimmune sera useful for diagnostic purposes. Non-human primates have also been useful in the titration of the infectivity of HAV isolates (33,34) and for in vivo intrahepatic cDNA transfection (47,48). They also represent a valuable tool in the analysis of obscure pathogenetic aspects of HAV infection (33,34,39-42,44,49-53), and for testing the safety and immunogenicity of candidate HAV vaccines (54-58). A formalin-inactivated hepatitis A vaccine was recently licensed for human use.
Hepatitis E virus (HEV)
Several species of non-human primates are susceptible to experimental HEV infection, as shown in Table 1 . The most useful of them have been cynomolgus and rhesus macaques (59-67). HEV was transmitted to primates by the iv (61, 63, 67) and oral routes (68), but the latter was shown to be less efficacious (69) .
The analysis of clinical and pathologic features in experimentally infected primates has contributed to a better understanding of the natural history of HEV infection, which is similar to that in man. Clinically overt hepatitis is observed in only half of the inoculated animals. The incubation period to peak liver enzyme levels is generally 3 to 8 weeks (59-61). The overall course of the infection appears to follow a rather predictable pattern, with detection of HEV antigen (HEVAg) in hepatocytes, virus excretion in the feces and viremia during the incubation period and early acute phase of disease (62) (63) (64) . Histopathologic changes in the liver parallel the seroconversion and biochemical evidence of hepatitis, with resolution in all cases. In addition, negative strands of HEV RNA replicative intermediates were detected in the livers of infected rhesus monkeys, which constitutes direct evidence of HEV replication in this organ (65) . The virulence of HEV does not seem to be increased by serial passages in monkeys (70) . Naturally acquired anti-HEV has been detected in wildcaught cynomolgus monkeys and captive rhesus monkeys (71) , suggesting that zoonotic spread of HEV may occur.
The primate model has helped elucidating aspects of the pathogenesis of HEV infection. First of all, the mechanism(s) by which HEV reaches the liver from the intestinal tract is unknown. The virus was found in the cytoplasm of hepatocytes, bile and feces during the second or third week after inoculation and prior to, or concurrently with the onset of ALT elevation and liver histopathologic changes (60, 63, 64) . This suggests that HEV may be released from hepatocytes into the bile before the peak of morphologic changes in the liver, during the highly replicative initial phase of infection. The involvement of the immune system in liver injury after HEV infection has also been unclear. The onset of ALT elevations and liver histopathologic changes generally corresponds to the rise of serum anti-HEV and decrease of HEVAg in hepatocytes. Infiltrating lymphocytes in the liver of HEV-infected cynomolgus were found to have a cytotoxic/suppressive phenotype (72) .
Human HEV infection causes substantial mortality due to fulminant hepatitis among pregnant women in some developing countries. The mechanism for this is completely undefined. Pregnant rhesus monkeys inoculated intravenously with a prototype HEV strain (SAR-55) at different stages of pregnancy did not develop disease of increased severity (67) .
Non-human primates have been used for testing the immunogenicity of recombinant HEV proteins expressed in insect cells (61) , and for titration of infectivity of prototype strains of HEV (69) . Another important application of primate studies was to find evidence of immune cross-protection between different isolates of HEV, which have been shown to be closely related at the genetic level (66) (73, 74) . Experimental studies in primates also suggest that passively acquired anti-HEV modifies but does not prevent HEV infection (75) .
Parenterally transmitted hepatitis viruses
Hepatitis B virus (HBV)
The only non-human primate that can develop productive HBV infection is the chimpanzee, which has served as the model for the study HBV infection for over 20 years. Experimental infections of gibbons, woolly monkeys, tamarins and other primate species were generally unsatisfactory. There has been uncertainty about whether baboons are susceptible to HBV infection since seropositivity for anti-HBs among baboons was found in a serologic survey of primate sera (76) . Baboons were also used as an animal model for the evaluation of the effect of adjuvant MF50 (Chiron) on the immunogenicity of recombinant hepatitis B vaccine (77) . In disagreement with this, Michaels et al. (78) failed to demonstrate even minimal viral replication during a 6-month follow-up using a highly sensitive PCR assay in two HBV-infected baboons, which is in accordance with previous observations by Deinhardt (4) . The resistence of baboons to HBV infection is of great interest for treatment strategies involving the use of liver xenotransplantation in patients suffering from end-stage liver disease secondary to chronic HBV infection.
The immunobiology of HBV infection in chimpanzees is similar to that observed in humans, except that the disease is generally less severe (79, 80) . After the incubation period of 4-10 weeks, the disease can be monitored by the elevation in liver enzymes, histopathological changes in liver tissue and the evolution of HBV markers (HBsAg, antiHBc, anti-HBs and HBV-DNA). HBcAg and HBsAg can be demonstrated in the hepatocytes of acute and chronically infected chimpanzees by immunohistochemistry.
HBsAg antigenemia can persist with progression to chronic infection, although substantially different from that observed in humans from both virological and pathological standpoints. Moreover, HCC was only rarely observed among chimpanzees infected with HBV (81, 82) . These facts, coupled with the severe limitation of chimpanzee availability, have led to the search for a more readily available animal for the investigation of the involvement of HBV infection in the etiology of HCC. Tree shrews, considered to be the lowest order of non-human primates, were successfully infected after inoculation with human serum positive for HBV (83) . Infections were passed successfully through five generations and could be prevented by immunization with hepatitis B vaccine. It remains to be known if tree shrews can develop chronic HBV infections and HCC. In another study, HBV was serially passaged in Macaca arssamensis, and 1 out of 7 animals developed HCC 2.5 years after inoculation (84) . In addition, non-primate laboratory animals, such as the woodchuck, Pekin duck, ground squirrel, and transgenic mouse have replaced the chimpanzee in many instances (85) . Although more distant from man than the chimpanzee, the eastern woodchuck (Marmota monax) is readily available, easy to handle and maintain, and much cheaper than the chimpanzee model (86) . It is naturally infected with woodchuck hepatitis virus (WHV), another member of the family Hepadnaviridae, closely related to HBV.
Different hepatitis B vaccines have been evaluated for safety and potential for inducing protective immunity in non-human primates, including subunit HBV vaccines (plasma-derived subviral particles and recombinant subunit proteins), and, more recently, DNA vaccines (87-89). The latter methodology was shown to induce anti-HBs serum levels in chimpanzees comparable to those induced by recombinant subunit vaccines (89) . Non-human primates are also used for the evaluation of neutralizing activity of hepatitis B immune globulin and antiHBs monoclonal antibodies (90) (91) (92) , and in the investigation of the effect of different adjuvants on the immunogenicity of hepatitis B vaccine (77) . Other applications are the study of the infectivity and pathogenicity of HBV strains including HBV genetic variants (93, 94) , and the infectivity titration of HBV strains (94, 95) .
Hepatitis C virus (HCV)
Due to the absence of an efficient in vitro system for HCV propagation, progress in the research of HCV biology depends almost entirely on infection studies carried out in chimpanzees, which represent the only reliable animal model for HCV infection. Almost all the knowledge of HCV biology was gained through experimental infection studies in this primate, mostly prior to the era of HCV molecular biology. A number of studies have provided information on the natural history of HCV infection in chimpanzees. A very early replicative phase is evident in these animals because hepatocytes are positive for viral RNA 1 to 2 days after experimental infection (96) . Specific HCV antigens are also demonstrated in hepatocytes within days of inoculation (97) . The paucity of positively stained cells suggests that the intracellular HCV load is small, which may be related to a slow viral replication rate and to the low level of HCV RNA typically found in serum. The possible existence of an extrahepatic site of HCV replication that could function as a reservoir of HCV remains controversial (98) . Viremia detectable by PCR occurs within 1 week of infection (99-101) and a pattern of intermittent viremia is observed until the major peak of serum transaminases at 8 to 16 weeks postinfection (102, 103) . In a recent study, it was shown that viremia levels in acute HCV infections in chimpanzees appeared to be at least 10-fold higher when the infection progressed to resolution than when it progressed to chronicity. During chronic infections, the viral load fell rapidly after the acute phase and remained low. After 4 to 6 years, the viral load and liver enzymes increased again, suggesting reactivation of the infection (104) . During the acute phase, seroconversion to one or more HCV antigens occurs concomitant with, or shortly after the peak of liver enzyme activity, but the antibody specificity patterns do not predict progression to chronicity (100,101). As in humans, HCV infection does not resolve in most animals; prospective studies indicate that 50 to 70% have persistent or intermittent viremia for at least 6 months after inoculation with HCV (102, 103) . A possible HCV-associated HCC was reported in one chimpanzee (105) . The liver of viremic chimpanzees presented HCVspecific CD8+ cytotoxic T lymphocytes (CTLs) which lysed target cells expressing viral proteins (106) . Anti-viral CTL are detectable in the liver during the acute phase of the disease, but are not sufficient to prevent the establishment of a persistent HCV infection (106) . Using the chimpanzee model, it was shown that CTL escape mutants can be selected with an enhanced ability to persist in the host (107) . The hypervariable region 1 (HVR 1) of the E2 protein changes continuously in hosts with chronic HCV infection, resulting in a quasispecies nature (108, 109) . A close relationship was found between sequence variation in the E2 region, but not the E1 region, and specific humoral immune response to linear epitopes, which is in keeping with an immune-selection mechanism of viral evolution (104) .
Although the development of a broadly reactive vaccine would be desirable for the control of hepatitis C, the high degree of genetic heterogeneity of HCV raises concerns about its feasibility. Studies in the chimpanzee model revealed that there was no cross-protection between different inocula. In fact, a second episode of hepatitis occurred even when the subsequent challenge was done with the same virus as used for inoculation (110, 111) . Chimpanzees have been protected against experimental challenge with HCV by prior vaccination with recombinant envelope glycoproteins (112), although doubts were expressed about the level of protection against heterologous HCV strains, the low dose and the short time for challenge after vaccination (113) . Post-exposure treatment with hepatitis C immune globulin significantly prolonged the incubation period of acute hepatitis C in chimpanzees, albeit without preventing the development of hepatitis C (114). More recently, two research groups have succeeded in the construction of a stable full-length cDNA clone of HCV, whose infectivity was demonstrated by the injection of RNA transcripts into the liver of a chimpanzee, resulting in viral replication (115, 116) .
Nowadays, chimpanzees are virtually unobtainable for research purposes and finding an alternative animal model constitutes a priority in this field. Studies with other nonhuman primates, most notably tamarin species (Saguinus mystax and Saguinus labiatus), have suggested that they may also be susceptible to non-A, non-B hepatitis viruses (117, 118) . However, these studies were undertaken before the non-A, non-B hepatitis virus group was identified and specific diagnostic tests for HCV were available. A recent study showed the lack of susceptibility of the cottontop tamarin (Saguinus oedipus oedipus) to HCV infection (119) . We have investigated the susceptibility of rhesus monkeys to HCV infection (120, 121) . Animals were inoculated intravenously with pooled HCV/RNA-positive plasma samples and the infection was widely monitored by biochemical, serological, histological and virological parameters for up to 70 days. The course of HCV infection was similar to that observed in the early acute phase of chimpanzee experimentally infected with HCV (99, 102) . Specific HCV antigen and peculiar ultrastructural changes were seen in liver along with increased ALT levels and HCV RNA in serum samples. Although animals have been followed for a relatively short period, the results are encouraging in terms of more prolonged studies in the future.
Hepatitis D virus (HDV)
The host range for productive replication of HDV is limited to those species that support the replication of a hepadnavirus capable of supplying a helper function. These include the chimpanzee (coinfected with HBV) and the eastern woodchuck (coinfected with WHV).
Chimpanzees were shown to be susceptible to infection with HDV shortly after the discovery of the delta antigen (23, 122) . Indeed, they were critical for the original identification of HDV as a distinct viral pathogen and since then have proved to be an invaluable source of information and material for the study of the biology and pathogenesis of HDV. However, only during the acute phase of infection does the chimpanzee model share some virological and histopathological features with humans. The acute phase may last for up to 7 months, with fluctuating serum ALT levels, and a pattern of immune response that is partially similar to that observed in humans: rising titers of total antibodies to HDAg (anti-HD) usually appear when ALT activities decrease (23), but anti-HD IgM antibodies are only occasionally seen and low-titered (123) . Persistent HDV infection has been documented in chimpanzee colonies at both the NIAID (123) and the Centers for Disease Control in Atlanta, GA, USA (124) . Similar to humans, chronicity is much more likely a result from superinfection than from coinfection (123) . However, chronic HDV in the chimpanzee is associated with only minor inflammatory changes, slightly altered ALT, and low levels of serum HDV RNA, while intrahepatic HDAg and IgM anti-HD are invariably absent (123, 125) .
The chimpanzee model has helped to elucidate the mechanisms by which HDV is transmitted to HBV-susceptible individuals (coinfection) or to HBV carriers (superinfection) (126) . It has also shown that the severity of the liver damage in the acute phase of infection is independent of the infectious dose (127) and correlates with passage number (125) . A decrease in the incubation period and an increase in pathogenicity are observed with serial passages in chimpanzees (125) . Characteristic cytoplasmic structures were also noted at the electron microscope level, similarly to those observed in human hepatitis C (99, 121) . The chimpanzee model has also been an invaluable source of material for the molecular characterization of HDV RNA (128) , and transfection experiments have been carried out by direct inoculation of a genomic-length complementary DNA (cDNA) clone of HDV in the liver of these animals (129) . However, a chimpanzee model for HDV infection is limited not only because this species is endangered, but also because the features of the chronic HDV infection in chimpanzees are substantially different from those observed in humans. For these reasons, chimpanzees have been replaced in many instances by the eastern woodchuck. As with HBV, the woodchuck has also proved to be a better model of the human disease associated with persistent infection with HDV, as well as for testing new antiviral agents (130) .
Conclusions
The rationale underlying the use of nonhuman primates in biomedical studies is that the evolutionary proximity of monkeys to human beings permits the reproduction and study of human diseases that cannot be examined in animals other than monkeys. Hepatitis viruses represent one of the most striking examples of this situation. Interestingly, the first experimental infection studies in non-human primates were carried out when the causative viruses had not yet been identified and methods for specific diagnosis were unavailable. In fact, specimens obtained from infected monkeys have been crucial for achieving both of these goals, and these models still represent an invaluable tool for the study of these viruses and for testing vaccines and antiviral drugs. Nevertheless, the use of non-human primates for experimental purposes has been subjected to severe regulations and restrictions. For this reason, efforts should be made to find alternative primate species, and to establish efficient cell cultures. 
